Download Files:
AT-130
$200 – $1,680
Products Details
Product Description
– AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells[1][2][3].
Web ID
– HY-100028
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– COVID-19-anti-virus
Molecular Formula
– C22H22BrN3O5
References
– [1]William E Delaney 4th, et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother. 2002 Sep;46(9):3057-60.|[2]R B Perni , et al. Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2687-90.|[3]J J Feld, et al. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 2007 Nov;76(2):168-77.
CAS Number
– 211364-06-6
Molecular Weight
– 488.33
Compound Purity
– 98.31
SMILES
– O=C(N/C(C(N1CCCCC1)=O)=C(Br)C2=CC=CC=C2OC)C3=CC=C([N+]([O-])=O)C=C3
Clinical Information
– No Development Reported
Research Area
– Cancer; Infection
Solubility
– DMSO : 25 mg/mL (ultrasonic)
Target
– DNA/RNA Synthesis;HBV
Pathway
– Anti-infection;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
